<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01253499</url>
  </required_header>
  <id_info>
    <org_study_id>TRx-037-003</org_study_id>
    <nct_id>NCT01253499</nct_id>
  </id_info>
  <brief_title>Multiple Dose Study of TRx0037</brief_title>
  <official_title>A Phase 1 Study Consisting of a Double-Blind, Placebo Controlled Multiple Dose Study of TRx0037 in Healthy Elderly Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TauRx Therapeutics Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Quotient Clinical</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>TauRx Therapeutics Ltd</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of
      TRx0037 after multiple doses in elderly volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bioavailability</measure>
    <time_frame>19 Days (7-10 day follow up)</time_frame>
    <description>The bioavailability of TRx0037 in an older population closer to the typical age range of the target patient population.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>19 Days (7-10 day follow up)</time_frame>
    <description>The pharmacokinetics for single doses of TRx0037 in healthy elderly volunteers.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>19 Days (7-10 day follow up)</time_frame>
    <description>Safety and tolerability measurements including adverse events, physical examination findings, vital signs, ECG, and clinical laboratory measurements for single doses of TRx0037</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>TRx0037</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Double blind placebo controlled study of TRx0037 in healthy elderly volunteers to assess safety, tolerability, bioavailability and pharmacokinetics</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TRx0037</intervention_name>
    <description>75mg and 100mg tablets used to create doses of 100mg and 175mg. Active placebo 2mg and blank placebo used as comparators.</description>
    <arm_group_label>TRx0037</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female 55 and over

          -  No clinically important abnormal physical finding

          -  No clinically significant lab results

          -  Normal ECG

          -  Normal BP and HR

          -  BMI between 19 and 32

          -  Weight 50 to 100 kg

          -  Able to communicate

          -  Provide written informed consent

          -  Non smokers

          -  Males to use contraception

          -  Females to be surgically sterile or post menopausal

        Exclusion Criteria:

          -  Administration of any IMP other than study drug within 12 weeks before entry

          -  Use of any prescribed meds, St John's wort, over the counter meds as described in the
             protocol

          -  Surgical or medical condition that might interfere with IMP

          -  History of drug or alcohol abuse

          -  Clinically significant allergy requiring treatment

          -  Loss of greater than 400ml of blood within 12 weeks.

          -  Serious adverse reaction or hypersensitivity to any drug

          -  Presence of Hep B, Hep c or HIV-1 or HIV-2 at screening

          -  Presence of G6PD at screening

          -  History of methaemoglobinaemia

          -  Partner who is pregnant of lactating

          -  Positive Pregnancy test
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stuart Dr Mair, MBChB</last_name>
    <role>Principal Investigator</role>
    <affiliation>Quotient Clinical</affiliation>
  </overall_official>
  <verification_date>December 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 2, 2010</study_first_submitted>
  <study_first_submitted_qc>December 2, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2010</study_first_posted>
  <last_update_submitted>December 16, 2010</last_update_submitted>
  <last_update_submitted_qc>December 16, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 17, 2010</last_update_posted>
  <responsible_party>
    <name_title>Professor Claude M. Wischik, Chairman</name_title>
    <organization>TauRx Therapeutics Ltd</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

